Upstream Bio, Inc. (UPB)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Developing Treatments for Inflammatory Diseases	2.85M	2.37M	2.38M	1.21M
Developing Treatments for Inflammatory Diseases Growth	20.42%	-0.42%	96.37%	-
Total	2.85M	2.37M	2.38M	1.21M
Total Growth	20.42%	-0.42%	96.37%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
United States	2.85M	2.37M	2.38M	1.21M
United States Growth	20.42%	-0.42%	96.37%	-
Total	2.85M	2.37M	2.38M	1.21M
Total Growth	20.42%	-0.42%	96.37%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 17, 2026

Data Sources Report a data error